Roivant Sciences Ltd (ROIV) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
Total Assets Chart for Roivant Sciences Ltd
Roivant Sciences Ltd (ROIV) total assets for FY2026 were USD 5.7B, a 5.4% change from FY2025. Roivant Sciences Ltd's total assets grew from USD 1.4B in 2019 to USD 5.7B in 2026 (312.7% over 7 years). Total assets compound annual growth rate: 5-year CAGR of 16.3%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $25.66B
- Implied Share Price
- $35.53
- Enterprise Value
- $22.86B
- Revenue (TTM)
- $7.53M
- EBITDA
- -$1.36B
- Profit Margin
- 0.00%
- Trailing P/E
- —
- Forward P/E
- 0.00
- Price/Book (MRQ)
- 6.29
- Price/Sales (TTM)
- 3407.35
- EV/EBITDA
- 0.74
- EV/Revenue
- 3035.18
- Dividend Yield
- —
- Book Value
- $5.86
- Free Cash Flow (FY2026)
- -$758.56M
- Free Cash Flow Yield
- -2.96%
Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.